Informing patients about serious side effects of drugs. A 2001 survey of 341 french rheumatologists

Joint Bone Spine

Volumn 70, Issue 1, 2003, Pages 52-57

  Berthelot, Jean Marie ^a   Glernarec, Joëlle ^a   Guillot, Pascale ^a   Chiffoleau, Anne ^a   Maugars, Yves ^a   Rodat, Olivier ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Information; Leaflet; Patient; Rheumatologist; Side effects; Toxicity

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; FRANCE; HEALTH SURVEY; HUMAN; INFORMATION; INTERPERSONAL COMMUNICATION; MUSCULOSKELETAL SYSTEM; PATIENT; PHARMACIST; PHYSICIAN; QUESTIONNAIRE; RHEUMATOLOGY; SCALE UP; SCORING SYSTEM; SIDE EFFECT;

ADULT; AGED; ANTIRHEUMATIC AGENTS; DISCLOSURE; HUMANS; MIDDLE AGED; PATIENT EDUCATION; PATIENT PARTICIPATION; PHYSICIAN-PATIENT RELATIONS; QUESTIONNAIRES; RHEUMATOLOGY; RISK ASSESSMENT;

EID: 0037298993     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1297-319X(02)00011-8     Document Type: Article

References (13)

1. Décret no 95-278 du 13 mars 1995, relatif à la pharmacovigilance et modifiant le code de la santé publique. Art. R.5144-4. Journal Officiel de la République Française.
2. Directive 2000/38/CE de la Commission du 5 Juin 2000 modifiant le chapitre V bis (Pharmacovigilance) de la directive 75/319/CEE du Conseil concemant le rapprochement des dispositions législatives, réglementaires et administratives relatives aux spécialités pharmaceutiques. Art. 29 ter. Journal Officiel no L 139 du 10/06/2000, p. 0028.
3. Décret no 95-278 du 13 mars 1995, relatif à la pharmacovigilance et modifiant le code de la santé publique. Art. R.5144-19. Journal Officiel de la République Française.
4. Kahn MF. L'information du patient. In: Kahn MF, Kuntz D, Meyer O, Bardin T, Orcel P, editors. L'Actualité Rhumatologique. Elsevier; 2000. p. 423-31.
5. Myllykangas-Luosujarvi R, Aho K, Isomaki H. Deaths attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died. J Rheumatol 1995;22:2214-7.
6. Berthelot JM, Saraux A, Chiffoleau A, Le Goff P, Maugars Y, Prost A. Sous-notification des effets secondaires létaux des médicaments. Importance du problème. Synoviale 2001;97:1-6.
7. Fraenkel L, Bogardus S, Concato J, Felson D. Unwillingness of rheumatoid arthritis (RA) patients to accept the risk of adverse effects (AES). Arthritis Rheum 2000;43(Suppl. 9):S141.
8. Ho M, Lavery B, Pullar T. The risk of treatment. A study of rheumatoid arthritis patients'attitudes. Br J Rheumatol 1998;37:459-60.
9. Pullar T, Wright V, Feely M. What do patients and rheumatologists regard as an 'acceptable' risk in the treatment of rheumatic disease? Br J Rheumatol 1990;29:215-8.
10. Herxheimer A. Leaflets with NSAIDs do not warn users clearly-a UK survey. Pharm J 1999;262:559-61.
11. Etchells E. A safe, effective adjunctive treatment for arthritis, and pretty much every other condition you'll ever treat. J Rheumatol 1999;26:1647-9.
12. Edworthy SM, Devins GM, and the Patient Education Study Group. Improving medication adherence through patient education distinguishing between appropriate and inappropriate utilization. Arthritis Rheum 1999;26:1793-801.
13. Pope JE, Stevens A, Rooks M. A randomised double-blind trial of verbal NSAID education compared to verbal and written education. J Rheumatol 1998;25:771-5.